the Efficacy and Safety of 5-HT3 Receptor Antagonist, Dexamethasone or Megestrol Acetate Dispersible Tablets in the Control of Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-09-07

Study Completion Date

2021-05-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To compare the efficacy and safety of megestrol acetate dispersible tablets combined with 5-HT3 receptor antagonist and dexamethasone triple antiemetic regimen and 5-HT3 receptor antagonist and dexamethasone combined antiemetic regimen in the control of CINV induced by hyperemetic chemotherapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Nano-crystalline Megestrol Acetate for Chemotherapy-induced Nausea and Vomiting

NCT07246070

Chemotherapy-Induced Nausea and Vomiting (CINV)

NOT_YET_RECRUITING PHASE2

Drugs to Reduce the Side Effects of Chemotherapy

NCT00003213

Nausea and Vomiting Unspecified Adult Solid Tumor, Protocol Specific

COMPLETED PHASE3

Evaluation of the Efficacy and Safety of Megestrol Acetate in Preventing Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy

NCT07130617

Efficacy Safety Megestrol Acetate +1 more

NOT_YET_RECRUITING PHASE1

Olanzapine or Dexamethasone, With 5-HT3 RA and NK-1 RA, to Prevent CINV

NCT04437017

Chemotherapy-induced Nausea and Vomiting

COMPLETED PHASE3

Dexamethasone Study: Impact on Quality of Life of Continuing Dexamethasone Following Emetogenic Chemotherapy

NCT00152867

Cancer Emesis Nausea

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

120 patients with malignant tumors diagnosed by pathology or cytology and treated with highly emetogenic chemotherapy drugs containing cisplatin from September 2018 to December 2019 were selected. The patients were randomly assigned to megestrol group (megestrol acetate dispersible tablets+5-HT3 receptor antagonist+dexamethasone) or control group (5-HT3 receptor antagonist + dexamethasone) at 1:1. The dosage of antiemetic drugs in the control group: 5-HT3 receptor antagonist 2.5mg, dexamethasone 12mg on the first day, 8mg on the 2nd-4th day, all were injected intravenously with 30min before chemotherapy for 5 days. The patients in the megestrol acetate group were given megestrol acetate dispersible tablets on the basis of the control group. 160 mg of megestrol acetate dispersible tablets were taken orally every morning on the day of the beginning of chemotherapy for 10 days. The main end point was the proportion of control of nausea and vomiting between the two groups during the delayed period (24-120 hours after the beginning of chemotherapy), that is, the proportion of complete remission (no vomiting and no need for rescue treatment) and complete prevention (no nausea and vomiting).The secondary end point was the control ratio of nausea and vomiting in the acute phase (0-24 hours after the beginning of chemotherapy) and the overall phase (0-120 hours after the beginning of chemotherapy); the proportion of patients with grade 3-4 nausea and vomiting during chemotherapy; the adverse reactions related to antiemetic drugs and the score of quality of life of patients in both groups before and after treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tumor Chemotherapy-induced Nausea and Vomiting

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Megestrol

Palonosetron 2.5mg, Dexamethasone 12mg on the first day, 8mg on the 2nd-4th day, Megestrol acetates 160mg orally every morning on the day of the beginning of chemotherapy for 10 days.

Group Type EXPERIMENTAL

Megestrol

Intervention Type DRUG

160 mg of megestrol acetate dispersible tablets were taken orally every morning on the day of the beginning of chemotherapy for 10 days.

5-HT3 receptor antagonist

Intervention Type DRUG

5-HT3 receptor antagonist 2.5mg/iv

dexamethasone

Intervention Type DRUG

dexamethasone 12mg on the first day, 8mg on the 2nd-4th day,

Control

Palonosetron 2.5mg, Dexamethasone12mg on the first day, 8mg on the 2nd-4th day

Group Type OTHER

5-HT3 receptor antagonist

Intervention Type DRUG

5-HT3 receptor antagonist 2.5mg/iv

dexamethasone

Intervention Type DRUG

dexamethasone 12mg on the first day, 8mg on the 2nd-4th day,

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Megestrol

160 mg of megestrol acetate dispersible tablets were taken orally every morning on the day of the beginning of chemotherapy for 10 days.

Intervention Type DRUG

5-HT3 receptor antagonist

5-HT3 receptor antagonist 2.5mg/iv

Intervention Type DRUG

dexamethasone

dexamethasone 12mg on the first day, 8mg on the 2nd-4th day,

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Megestrol acetate

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Tumor patients diagnosed by histopathology or cytology, as long as the chemotherapy with cisplatin is used, the amount of cisplatin is 60-80 mg/m2;
* Unlimited gender, age 18 to 70 years old;
* ECOG physical status score 0-1;
* The survival time is predicted to be more than 3 months;
* Bone marrow hematopoietic function was not significantly impaired (WBC≥3.5109/L, ANC≥1.5109/L, PLT≥100109/L, Hb≥100g/L);
* Biochemical examination AST / ALT ≤ 2.5 times the upper limit of normal; bilirubin ≤ 1.5 times the upper limit of normal; creatinine clearance ≥ 60ml / min, normal ECG;
* Signing informed consent;

Exclusion Criteria

* Women who are pregnant or breastfeeding, women of childbearing age who refuse to receive contraception;
* Brain metastasis;
* Combine all of the following serious or uncontrolled diseases that affect participation in the trial: Uncontrollable hypertension, history of unstable hypertension, or poor adherence to antihypertention drugs; Unstable angina; Symptomatic congestive heart failure; Myocardial infarction occurred within 6 months before enrollment; Severe uncontrollable arrhythmia; Uncontrollable diabetes; Active or uncontrollable infection; Intestinal paralysis, intestinal obstruction, interstitial pneumonia, active gastric ulcer; Subject to immunosuppressive therapy;
* Inability to understand or express informed consent;
* The investigator judged other conditions that were not suitable for clinical research.

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes